BlueLight

About BlueLight

BlueLight Therapeutics, operating as a private biotechnology firm, concentrates on the discovery and development of novel therapeutic molecules aimed at high-value drug targets that are traditionally difficult to address. The company was established in 2000 under the name Biodesy Inc. and officially rebranded to BlueLight Therapeutics on May 20, 2020, to better align its identity with a long-term strategic focus on creating small molecule therapeutics. The firm is backed by a consortium of venture capital investors, including 5AM Ventures, Pfizer Ventures, and Alexandria Venture Investments.

The core of BlueLight's operation is its proprietary, structure-driven discovery platform. This platform utilizes a technology known as Second Harmonic Generation (SHG) to monitor the structural changes, or conformations, of biomolecules in real-time and at a high throughput. By observing how these molecules change shape to regulate biological activity, BlueLight can identify and develop compounds that induce a specific, functionally relevant structural state in a target protein. This methodology offers a distinct advantage over conventional screening techniques by enabling the discovery of drug candidates with novel mechanisms of action, particularly for challenging targets in disease pathways. The initial therapeutic area of focus for the company has been oncology.

The management team comprises experienced professionals from the biotechnology and venture capital sectors. The Chief Executive Officer, Ariel Notcovich, has a background in physics and prior entrepreneurial success, having founded ProteOptics, which was later acquired by Bio-Rad Laboratories. The leadership also includes Mark Gallop as Chief Scientific Officer, Mira Chaurushiya as Chief Business Officer, and Anjanabha Saha as VP of Discovery, all of whom bring significant experience from firms like 5AM Ventures, Nurix, and Genentech.

BlueLight Therapeutics engages with the biopharmaceutical industry by forming partnerships to advance the discovery and development of new treatments for difficult targets. Its business model is centered on leveraging its unique platform to build a sustainable pipeline of drugs. The company is headquartered in South San Francisco, California.